ClinicalTrials.gg
RecruitingNCT06844045Updated May 5, 2026

Point of Care STI Testing

An interventional study of Gonorrhea/chlamydia Point-of-Care Testing in Point of Care STI Testing, sponsored by Icahn School of Medicine at Mount Sinai. Recruiting at 1 site in United States. Open to participants aged 16 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
6,460
Allocation
Non-randomized
Ages
16 Years to 24 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 98 studies in Gonorrhea with a site in United States — 11 open to participants now, 11 under way, none of them phase 3. Gonorrhea · United States.

Planned enrollment
4th of 76
6,460 · median 341
Started
2026
with 3 others
No phase
38 of 98
9 open now
Primary completion
2026-12
later than 2 of 10 live
Registered
94th of 98
by date

Among the 98 studies in Gonorrhea with a site in United States, this one is the 4th largest by planned enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2026, is one of 38 with no phase, reaches primary completion later than 2 of the 10 other live ones, and was the 94th registered.

Gonorrhea

168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.

Browse Gonorrhea studies →

Open to participants now

11 of the 98 studies in Gonorrhea with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Gonorrhea studies recruiting now, 11 (61%) set no upper age limit and 6 (33%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 16 Years to 24 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Gonorrhea with a site in United States, or all of them as a file.
02

Study summary

The proposed research hypothesizes that point-of-care testing (POCT) for sexually transmitted infections (STIs) gonorrhea and chlamydia will be a feasible, acceptable, and appropriate implementation strategy for improving HIV testing and Pre-exposure prophylaxis (PrEP) delivery in youth, by increasing opportunities for clinician-patient counseling, decreasing loss to follow up, and allowing for same-day HIV prevention service provision. This hypothesis will be tested in a pragmatic non-randomized trial comparing clinical (HIV testing and PrEP counseling and prescription) and implementation (feasibility, acceptability, and appropriateness) outcomes between adolescents receiving POCT compared to laboratory-based testing at three clinics within a large pediatric health system.

03

Conditions studied

  • Point of Care STI Testing

Keywords

  • HIV Prevention
  • HIV Testing
  • HIV Pre-Exposure Prophylaxis
  • Gonorrhea
  • Chlamydia
  • Sexually Transmitted Infections
04

Who can participate

Ages eligible
16 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patients age 16-24 years receiving POCT or lab-based GC/CT testing

Exclusion criteria

Exclusion Criteria:

- Patients with known or active PrEP prescriptions.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
6,460 participants (estimated)

Study arms

  • Experimental
    Point-of-Care Tested

    Participants in the intervention arm have received point-of-care testing for sexually transmitted infections.

    Behavioral: Gonorrhea/chlamydia Point-of-Care Testing

  • No intervention
    Lab Tested

    Participants in the control arm have received lab-based testing for sexually transmitted infections.

Interventions

  • BehavioralGonorrhea/chlamydia Point-of-Care Testing

    Point-of-care testing for sexually transmitted infections.

06

What researchers measure

Primary outcomes

  1. Rates of HIV Test Completion

    Rates of HIV test completion on the day of gonorrhea/chlamydia testing will be compared between those who receive point-of-care vs. lab-based STI testing.

    Time frame: Day 1 - Measured on date of STI testing

Secondary outcomes

  1. Number of participants who received PrEP counseling

    PrEP counseling will be measured using visit note data from the date of the STI testing encounter

    Time frame: Day 1 - Same day as STI testing encounter

  2. Time to STI treatment

    Days between STI test order and delivery of antibiotics for STI treatment, measured using EHR data

    Time frame: Time from STI diagnosis to treatment, up to 9 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All of the individual participant data collected during the trial, after deidentification.

Supporting information: Study protocol, Informed consent form, Analytic code

Time frame: Specify Other Time Frame After the end of the award period. No end date.

Access criteria: Researchers who provide a methodologically sound proposal. Any purpose. Data will be findable for the research community through the NIHM Data Archive Collection.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 37 non-industry interventional studies with no phase under Gonorrhea, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 10 months is below that.

Counting every sponsor, half of 41 studies reached it within 23 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Feb 24, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
May 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06844045
Responsible party
Sarah Wood (Associate Professor, Icahn School of Medicine at Mount Sinai) — Principal investigator
First posted
Feb 25, 2025
Start date
Feb 24, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Naomi Pressman, MS, RD
Contact
naomi.pressman@mountsinai.org
(212) 731-7810
Sarah Wood, MD, MSHP
principal investigator · Mount Sinai Adolescent Health Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion